- Home
- KRC vs VERA Comparison
KRC vs VERA Comparison
Compare KRC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | VERA |
|---|---|---|
| Founded | 1947 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.4B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KRC | VERA |
|---|---|---|
| Price | $35.00 | $43.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | $41.33 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 02-09-2026 | 02-25-2026 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | ★ 62.23 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $1,126,859,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.59 | N/A |
| P/E Ratio | $12.66 | ★ N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $27.07 | $18.53 |
| 52 Week High | $45.03 | $56.05 |
Technical Indicators
Market Signals| Indicator | KRC | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 30.86 | 42.76 |
| Support Level | $33.82 | $40.87 |
| Resistance Level | $34.76 | $45.51 |
| Average True Range (ATR) | 0.78 | 2.18 |
| MACD | -0.03 | -0.67 |
| Stochastic Oscillator | 22.00 | 22.10 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.